Ideas Discussions Themes Map Live Ask AI

All beneficiaries

company

Merck & Co.

Information not available.

No information was found regarding this entity in the provided research brief.

Ideas that could help Merck & Co.

Pre-Treatment Tumor Potency-State Report for Immunotherapy StratificationWhy it helps: As the pembrolizumab developer, it faces exactly the responder-identification gap documented in [1]; a baseline potency-state stratifier could enrich responder populations in its checkpoint-inhibitor trials.
Post-Vaccine PD-L1 Conversion Test for Cold TumorsWhy it helps: Maker of Keytruda; a test that converts PD-L1-negative cold-tumor patients into eligible patients expands the population that can benefit from its drug.
EpitopeLock: De Novo Nanobody Design Service with Structure-Verified Epitope TargetingWhy it helps: Markets Zinplava (bezlotoxumab) against C. difficile toxin B; the paper's TcdB epitope-specific VHHs, scFvs, and full IgG1 provide a direct route to next-generation anti-toxin programs.
Perioperative-or-Surgery-Alone Decision Aid for Cisplatin-Ineligible Bladder CancerWhy it helps: Maker of pembrolizumab and sponsor of the trial; a validated shared decision aid supports informed, appropriate uptake of the perioperative regimen it co-developed.
Cisplatin-Ineligibility Flag for Pre-Surgery Bladder Cancer ReferralWhy it helps: Pembrolizumab's perioperative benefit likewise requires pre-surgery initiation; the triage flag drives earlier medical oncology referral where the regimen can be offered.
Post-Ablation Chaperokine Response Blood TestWhy it helps: Operates many pembrolizumab combination trials; a biomarker identifying patients who mount an endogenous Hsp70-driven immune response after ablation could enrich ablation + PD-1 study populations.

Recent research, turned into concrete, commercially plausible innovation ideas — each with an interactive prototype you can try.

Explore

Ideas
Discussions
Themes
Live
Research
Map
Personas
Who benefits
Ask AI

For you

For researchers
For industry
For investors

Learn more

About
How it works
FAQ

Account

Sign in
Your space
Your stream
Your digest
Your contexts
Your data

© 2026 SeedlabsRecent research, turned into shippable ideas.